A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...
The multiple sclerosis market presents opportunities in developing innovative therapies, leveraging collaborations, and advancing clinical trials. Key players focus on new drug mechanisms and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results